Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

115.80 -0.78 (-0.67%)
Official Closing Price Updated: 6:30 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,693,232
Open 116.66
Bid (Size) 114.56 (1)
Ask (Size) 115.80 (1)
Prev. Close 116.58
Today's Range 114.47 - 116.73
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
From Merck & Co., Inc.
Via Business Wire
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+2.26%
+2.26%
1 Month
+3.11%
+3.11%
3 Month
-10.03%
-10.03%
6 Month
-5.72%
-5.72%
1 Year
+7.71%
+7.71%

More News

Read More
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Via Benzinga
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Via Chartmill
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Options: An Unlikely Source Of Income
Via Talk Markets
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
2 Dividend Stocks You Can Safely Hold Through a Recession
Via The Motley Fool
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Via Benzinga
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
From Merck & Co., Inc.
Via Business Wire
Dow Jones Industrial Average Pares Recent Gains As Investors Take A Pause
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Dividend Stocks to Earn Income Every Month
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
Via The Motley Fool
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
From Merck & Co., Inc.
Via Business Wire
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
From Merck & Co., Inc.
Via Business Wire
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
MarketBeat Week in Review – 8/19 - 8/23
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.